Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.69% 35.75p 35.50p 36.00p 36.00p 35.50p 36.00p 20,097 09:10:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 26.75

Angle Share Discussion Threads

Showing 46926 to 46949 of 46950 messages
Chat Pages: 1878  1877  1876  1875  1874  1873  1872  1871  1870  1869  1868  1867  Older
DateSubjectAuthorDiscuss
20/9/2017
05:02
ANGLE plc, a liquid biopsy company, has secured a valuable partnership with molecular testing giant Qiagen and an exclusive option agreement with Queen Mary University of London. ANGLE is known for Parsortix, its novel system for capturing and harvesting circulating tumor cells (CTCs) from blood. A Large Selling Opportunity with Qiagen The co-marketing partnership with Qiagen isn’t just a major win for ANGLE—it will also give Qiagen, which has more than 500,000 customers, an additional opportunity in the liquid biopsy space and the ability to offer ANGLE’s unique CTC harvesting technology alongside its own downstream analysis techniques. ANGLE founder and CEO Andrew Newland explained, “With very little modification, [Qiagen will] be able to flow through Parsortix cells from blood and produce extra revenues out of their existing installed base.” He added, “This is absolutely key to our strategy, to partner with the large companies who’ve got the downstream analysis technologies, because they’re the ones who’ve got the big sales and distribution channels and can basically promote and sell our product.” The partnership is not exclusive. Initially, the co-marketing partnership will focus on research-use sales for prostate cancer and breast cancer. Newland noted that there is not yet a CTC solution cleared by FDA for clinical applications, though ANGLE is conducting research, including a study with MD Anderson, to secure regulatory go-ahead. Qiagen assessed the Parsortix system for several months before signing on to the co-marketing relationship. Newland pointed to three main advantages of the Parsortix system over other CTC technologies. First, because the system is epitope-independent and doesn’t use antibodies to capture CTCs, it can capture all types of CTCs, not just epithelial-based cells. “There’s a separate subset of circulating tumor cells, the mesenchymal circulating tumor cells. These are the ones that have been through the transition and are the ones actively promoting the spread of the cancer. None of the antibody-based systems can get those cells,” he said. In addition, the cells captured with Parsortix are not damaged by the harvesting process. “They come out pristine, still alive, exactly as they were in the patient,” Newland said. Lastly, the system is highly sensitive and can capture CTCs from almost all patients, he added. “ANGLE's Parsortix system is a unique, epitope-independent CTC solution offering easy, automated processing of whole blood to harvest all types of CTCs, including the clinically relevant mesenchymal CTCs, for analysis,” Michael Kazinski, Qiagen’s senior director of Molecular Preanalytic Technologies, said in a press release. “It complements very well with our AdnaTest CTC portfolio, now allowing for both phenotypic and molecular characterization of CTCs. The modular combination abilities of this system with QIAGEN's liquid biopsy-based Sample to Insight offering, including AdnaTest, our targeted RNAseq and single cell solutions, along with our bioinformatics offering, will allow scientists and clinical researchers to significantly advance their research.” A New Area of Interest ANGLE also recently signed an option agreement with Queen Mary University of London (QMUL) for an exclusive global license covering the intellectual property related to new findings on the potential importance of megakaryocytes in cancer. The Parsortix system is the only available technology for harvesting megakaryocytes, according to the company. Recent research from Barts Cancer Institute at QMUL, published in Clinical Cancer Research, revealed that the number of megakaryocytes in a prostate cancer patient's blood may be associated with that patient’s prognosis. The study found that higher numbers of megakaryocytes were correlated with higher survival rates. QMUL is pursuing two worldwide patents on the discovery. “We believe the patents on the role of megakaryocytes in patient blood as a favourable prognostic biomarker has the potential to open up new avenues of research in the fight against cancer,” Michele Hill-Perkins, head of Technology Transfer Biopharma at QMUL Barts Queen Mary Innovation Ltd, said in a press release. “We are delighted to have signed this deal with ANGLE to progress their commercialization for the benefit of patients.” This first-of-its-kind finding is significant because it might eventually enable cancer patients to receive a simple blood test that uses mesenchymal CTCs and megakaryocytes to determine disease prognosis. The ANGLE-QMUL agreement gives ANGLE a two-year option to an exclusive worldwide license on the QMUL patents. Newland described the agreement as strengthening ANGLE’s commercial position. “People can harvest [megakaryocytes] using other techniques, but what they can’t do is use the numbers of those cells to predict the prognosis of patients.” He added, “In the future, we hope that we’ll have a blood test that will . . . tell people—have you got cancer, and if so, does it need treatment?”
flavio_monteiro
19/9/2017
22:29
Cheers Bermuda, thanks for sharing.
maxie23
19/9/2017
22:23
Good stuff Bermuda.
semper vigilans
19/9/2017
22:09
Excellent article Bermuda, not seen that one before..
willfy
19/9/2017
21:53
Not sure whether this has already been posted, but nice article below covering latest developments here:- hTTps://www.mddionline.com/qiagen-partners-cell-diagnostics-company
bermudashorts
19/9/2017
15:54
AN seemed very excited (in the proactive video) about the research that was going to be presented at the conference in early Oct. Hopefully this will generate some decent newsflow.
miavoce
19/9/2017
15:51
Meant to say everything bar the share price , though with the AGM approaching , would hope significant news will be released
willfy
19/9/2017
14:35
The share price isn't gaining traction Willfy.
semper vigilans
18/9/2017
20:56
Certainly gaining traction, good find Miavoce
willfy
18/9/2017
20:20
Mayflower Bioscience appear to be distributing Parsortix...I wonder if AGL know ? hTTp://www.mayflowerbio.com/products/parsortix-cell-separation-system
miavoce
18/9/2017
19:38
Think they need to focus on any sales they can get tbh. Chart is poised either a repeat of the start of August where it rose then fell or breaks out into positive territory . Next week or so will dictate . Funding may well provide th answer as it's still not gone away
bones698
18/9/2017
14:15
Fitzpatrick Referrals has a very strong relationship with the Univ. of Surrey. With Angle based just across the road I'd be extremely surprized if neither knew about the other.
outsizeclothes.com
17/9/2017
17:00
Noel Fitzpatrick (The Bionic Vet) i'm sure could well afford a Parsortix machine to try it out.
maxie23
17/9/2017
08:21
I've always thought that it would be extended to veterinary use at some point - its amazing what people will spend on the health of their animals and the pet insurance is becoming very common.
miavoce
16/9/2017
22:18
Probably right, though sometime down the line, there is probably potential for the use of Parsortix, apart from cancer, which a third party could take on.
4legs
16/9/2017
21:56
Looks like they are just repeating what Angle have published about their business
miavoce
16/9/2017
21:40
msn money section about Angle describes it as a diagnostic company with products in cancer diagnostics and foetal health.
4legs
16/9/2017
21:18
For some reason the Parsortix cassette animation video with the Telegraph logo has been posted on msn.com within the last hour. I wonder if this indicates that we are to get some Sunday press (although the video has been included in one of the previous Telegraph articles about Parsortix so it might just be a random posting on msn).
miavoce
16/9/2017
20:23
From 2010 interims: Parsortix (80%) (medical diagnostics) has extended its IP protection with new patent submissions covering its capture of whole foetal cells from maternal blood (rather than just DNA fragments), circulating tumour cells (CTC), bacteria and stem cells.
4legs
16/9/2017
19:50
It is odd that they have kept the reference to Fetal Health in the description of their business - either they plan to revive Novocellus at some point or they plan to use Parsortix to capture foetal cells from blood (which I believe was the original intended purpose for Parsortix before they realised it could capture cancer cells).
miavoce
16/9/2017
18:16
In which case I assume there is something going on superior to Novocellus?
semper vigilans
16/9/2017
17:45
Hi Willfy Angle include Fetal Health in their own description of themselves on the website:- "ANGLE plc is a commercially driven medical diagnostic company specializing in the development of pioneering products in the fields of cancer diagnostics and fetal health." I guess they have paraphrased this.
miavoce
16/9/2017
17:38
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health.This is from finncap latest release last Monday, don't ever recall seeing any mention about Fetal Health before on any broker notes....
willfy
16/9/2017
14:46
How does Grail compare with Parsortix? They received $900 million in funding. I've just read about it in the Economist which has a feature on cancer with, surprise surprise, NO mention of the market leader. If Grail can raise $900m we may as well give up.
honestguv
Chat Pages: 1878  1877  1876  1875  1874  1873  1872  1871  1870  1869  1868  1867  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170921 08:50:39